Skip to content

Transcode Therapeutics, Inc.

RNAZ

CIK 0001829635 · Pharmaceutical Preparations · Nasdaq

← back to feed
Revenue (TTM)
—
Q1 May 2026
Net Income (TTM)
−$39M
−106.9% YoY Q1 May 2026
EPS Diluted (TTM)
−$102.39
+96.1% YoY Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
—
Q1 May 2026
Net Margin
—
Q1 May 2026
Free Cash Flow (TTM)
−$16.65M
Q1 May 2026
Cash
$12.84M
Q1 May 2026
Total Debt
—
Q1 May 2026
Shares Outstanding
950.3K sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Cash vs Debt

Recent filings